Jc. Tonn et al., INVASIVE BEHAVIOR OF HUMAN GLIOMAS IS MEDIATED BY INTERINDIVIDUALLY DIFFERENT INTEGRIN PATTERNS, Anticancer research, 18(4A), 1998, pp. 2599-2605
Background: Glioma invasion is still a major obstacle for successful t
herapy. In the past we could demonstrate that glioma invasion is media
ted by different adhesion molecules of the integrin family. Here we in
vestigated whether a common pattern of integrin profiles might be invo
lved, potentially providing a therapeutical avenue. Material and Metho
ds: Multicellular spheroids were generated out of three human cell lin
es (GaMG, U373, U251) and from tumor biopsies of 9 human glioblastomas
. After confrontation with rat brain aggregates, functional blocking a
ntibodies against different integrin subunits (alpha 2 alpha 3, alpha
nu, alpha 1, alpha nu beta 3, alpha nu beta 5) or four different disin
tegrines (kistrin, echistatin, eristostatin, flavoridin) were added. I
ntegrin patterns of the human cell lines/specimens were determined by
FACScan or immunohistochemistry. Results: In cell lines, antibodies ag
ainst alpha 2, alpha 3, alpha nu and alpha nu beta 5 effectively reduc
ed invasion into rat brain aggregates. Little effect could be observed
with the anti-beta 1- or with anti-alpha nu beta 3- antibodies. In pr
imary tumor specimens, however, a different invasion pattern in regard
to ifs integrin dependency emerged with antibodies against the alpha
3-chain or the alpha nu beta 3 integrin being the most effective Invas
ion of primary tumor tissue into the brain aggregates was by far more
aggressive compared to that bf the cell lines. Accordingly, it was les
s influenced by integrin antibodies. The disintegrines affected migrat
ion of glioma cells on purified ECM substrates in a heterogeneous matt
er, but had no impact on tumor invasion into brain aggregates. Conclus
ion: Although invasion of human gliomas is mediated by integrins, due
to the heterogeneity of its dependency on different integrins this app
roach seems not to be appropriate to sufficiently alter glioma invasio
n in a therapeutical neuro-oncological setting.